Upfront Briefing
Lilly signed up Beijing's InnoCare for five discovery targets at $100M upfront in Trump-Xi summit week, and Enveda banked a $311M crossover Series E at a ~$2B valuation, double last year's mark. Roche's once-monthly sefaxersen hit its Phase 3 IgAN proteinuria goal, walking straight into Novartis' Fabhalta, and Grail got its FDA panel yes with an asterisk: 7-2 on benefit-risk, only 6-4 on whether it works.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,706.0 |
(0.8%) |
12.6% |
| Nasdaq 100 |
30,470.3 |
(0.9%) |
20.9% |
| Russell 2000 |
2,838.7 |
(1.8%) |
14.4% |
| Healthcare (XLV) |
168.8 |
(0.6%) |
9.0% |
| Biotech (XBI) |
155.2 |
(4.1%) |
27.3% |
| Nasdaq Biotech (NBI) |
7,015.5 |
(2.1%) |
22.9% |
| Clinical Trials (BBC) |
46.7 |
(6.4%) |
24.0% |
|
- Clinical-stage biotech took the heaviest hit in a rate-led selloff: BBC fell 6.4% and XBI 4.1%, against NBI (2.1%) and XLV (0.6%), a clean duration gradient with no single sector catalyst behind it.
- Macro: a hot S&P Global flash PMI pushed the 10-year Treasury yield to about 5.13% intraday, its highest since July 2007, and revived Fed-hike talk; the S&P 500 fell 0.75%, the Nasdaq 100 0.85% and the Russell 2000 1.8%, with crude up ~2% after Trump's UN remarks on Iran. Trump hosts Xi in Washington this week.
- Market data: U.S. cash close Wednesday, 23 September 2026.
The Big 3
|
1
|
InnoCare lands $100M from Lilly in a five-target, $3.35B pact
|
- Beijing-based InnoCare (HKEX: 9969) will discover compounds against up to five undisclosed targets for Lilly for up to $100M upfront and near-term, ~$3.25B in development and commercial milestones, and single-digit tiered royalties.
- Why it matters: Strip out the headline and this is a discovery deal: $100M upfront and near-term against five unnamed targets, roughly $20M a target, with 97% of the $3.35B sitting in milestones years out. Lilly is buying chemistry throughput from a profitable, commercial-stage partner with three marketed drugs, not a de-risked asset, the same platform-access logic as its QurCan CNS pact earlier this month. The read-through is to Hong Kong-listed China discovery shops, where target-level deals are becoming a financing line in their own right. The risk is political: COINS Act language on China-sourced biotech remains live, and a signing during Trump-Xi summit week will not go unnoticed on Capitol Hill.
- Source: Fierce Biotech
- More: InnoCare release
|
|
2
|
Enveda banks a $311M crossover Series E at a ~$2B valuation
|
- AI natural-products drug hunter Enveda closed a $311M Series E led by Catalio Capital Management at a ~$2B valuation, double its mark of a year ago, with Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (Citadel) and T. Rowe Price new to the register; total raised now exceeds $845M.
- Why it matters: A crossover-heavy Series E at a doubled ~$2B mark reads as IPO pre-positioning. The clinical base is thin for that price. ENV-308, an oral mimic of the exercise-induced molecule Lac-Phe aimed at keeping weight off after GLP-1 withdrawal, has shown Phase 1 tolerability rather than efficacy, and ENV-294 has one early atopic dermatitis readout. Same-day comps frame the AI premium: Basecamp priced its $140M Series C at ~$800M on preclinical assets. The risk is timing; with the 10-year above 5%, the listing window that justifies this mark can shut before ENV-308 produces a weight number.
- Source: Fierce Biotech
- More: BioPharma Dive
|
| 3 | Roche's monthly sefaxersen hits Phase 3 IgAN proteinuria goal |
- A prespecified interim of Roche's Phase 3 IMAgINATION met its primary endpoint, a statistically significant cut in 24-hour UPCR vs placebo at week 37, for the Ionis-partnered, once-monthly self-injected factor B antisense drug; effect size undisclosed, data headed to a congress and regulators.
- Why it matters: No effect size was disclosed, so the market is pricing a hit rather than a profile. Proteinuria is the surrogate that carried Novartis' Fabhalta, also a factor B play, to accelerated approval in IgAN, and analysts already expect an accelerated U.S. filing on this interim. The commercial pitch is convenience: a monthly self-injection against twice-daily oral iptacopan, which carries a REMS for encapsulated-bacteria infections, while Vera's atacicept attacks the disease upstream via BAFF/APRIL. Ionis holds milestones and tiered royalties, not the P&L. The risk sits at the congress readout: an unremarkable UPCR delta would turn best-in-class language into also-ran in a market where several mechanisms already compete for the same nephrologists.
- Source: Fierce Biotech
- More: BioPharma Dive
|
Everything Else that broke
- An FDA advisory panel backed Grail's Galleri multi-cancer screening test 7-2 on benefit-risk and 10-0 on safety but split 6-4 on effectiveness; FDA has set no action date on the January PMA. — STAT
- Immunovant stopped developing IMVT-1402 in cutaneous lupus after the anti-FcRn antibody failed a Phase 2 test. — Fierce Biotech
- At IMS in Glasgow, BMS's mezigdomide plus Pfizer's Elrexfio produced responses in all 13 evaluable relapsed/refractory myeloma patients in part 1 of the Phase 1/2 MELT-MM study. — Targeted Oncology
- FDA nominee Heidi Overton told her Senate hearing she would speed clinical research and address China competition. — STAT
- Lilly said it holds 70% of Medicare's GLP-1 program as enrollment reached 700K seniors. — Fierce Pharma
- Novo Nordisk's CEO said the company is open to an upgraded NYSE listing, though no transition is underway. — Fierce Pharma
- The Department of War awarded Flagship Pioneering $47M to develop medical countermeasure technologies against emerging threats. — Fierce Biotech
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Lilly / InnoCare: five-target discovery collaboration and licence, up to $100M upfront and near-term, ~$3.25B milestones, single-digit tiered royalties. — Fierce Biotech
- Boehringer expanded its Variant Bio collaboration into cardiovascular disease, adding $250M in deal value. — Fierce Biotech
- Zymeworks closed its $17/share cash takeout of Theravance (~$929M equity value, signed 29 June), funded with cash and new debt; holders also get an ampreloxetine CVR. — GlobeNewswire
VC / Private Financings
- Enveda closed a $311M Series E at a ~$2B valuation, led by Catalio Capital Management, joined by Durable Capital Partners, ICONIQ, Lightspeed and T. Rowe Price; proceeds take ENV-308 (post-GLP-1 weight maintenance) and ENV-294 (atopic dermatitis) into later-stage trials. — BioPharma Dive
- Basecamp Research raised a $140M Series C at a reported ~$800M valuation, led by S32, joined by NVIDIA, Anthropic's Anthology Fund, the NATO Innovation Fund and Catalio, to train next-gen EDEN models and push in vivo cell therapy toward the clinic. — Endpoints
IPOs / Follow-Ons
- Viking launched $200M of common stock plus $200M of 2032 convertible notes (each with a $30M option) via Morgan Stanley and J.P. Morgan after Wednesday's close; pricing not yet announced at scan. — PR
Academic Corner
- A Nature Reviews Drug Discovery review examined how IL-6 signalling selectivity could refine autoimmune drug development. — Nature RDD
|
